ONCOMING 2026: Abordando el Futuro del Manejo del Cáncer de Ovario

El pasado 12 y 13 de marzo tuvo lugar la sexta edición de ONCOMING, en la que más de 100 asistentes se dieron cita en Madrid para abordar juntos los retos actuales en el manejo del cáncer de ovario y analizar la innovación clínica que hay detrás de la evolución en la práctica clínica asistencial.

¡Accede ahora a los recursos de la reunión y solicita las presentaciones!

BRCA: Gen de susceptibilidad al cáncer de mama; CRS: Score de respuesta de quimioterapia; HEaLS: Health Evidence achieving Long Survival; HRD: Deficiencia de recombinación homóloga; iPARP: Inhibidores de la poli (ADP-ribosa) polimerasa; KELIM: Cinética de eliminación de CA-125; SEAP: Sociedad Española de Anatomía Patológica; SEOM: Sociedad Española de Oncología Médica; 1L: Primera línea.

1. Chiva L, Ordas P, Mishra J, et al. SUROVA study: global real-world treatment strategies and mortality risk prediction in advanced ovarian cancer. Int J Gynecol Cancer. 2025 Dec;35(12):102688.
2. Perren TJ, Swart AM, Pfisterer J, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011 Dec 29;365(26):2484-96. 
3. Burguer RA, Brady MF, Bookman MA, et al. Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer. N Engl J Med. 2011;365:2473–2483
4. Moore K, Colombo N, Scambia G, et al. Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. N Engl J Med. 2018 Dec 27;379(26):2495-2505. 
5. Ray-Coquard I, Pautier P, Pignata S, et al. Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer. N Engl J Med. 2019 Dec 19;381(25):2416-2428. 
6. Sghaier S, Corbaux P, Ray-Coquard I, et al. NIRVANA-1: maintenance therapy with niraparib versus niraparib-bevacizumab in patients with advanced ovarian cancer. Future Oncol. 2023 Aug;19(25):1715-1727. 
7. González-Martín A, et al. Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. N Engl J Med. 2019 Dec 19;381(25):2391-2402. 
8. Coleman RL, Fleming GF, Brady MF, et al. Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer. N Engl J Med. 2019 Dec 19;381(25):2403–15.
9. Monk BJ, Parkinson C, Lim MC, O’Malley DM, Oaknin A, Wilson MK, et al. A randomized, phase III trial to evaluate rucaparib monotherapy as maintenance treatment in patients with newly diagnosed ovarian cancer (ATHENA-MONO/GOG-3020/ENGOTov45). J Clin Oncol. 2022;40(34):3952–64
10. Hardy-Bessard AC, Pujade-Lauraine E, Moore RG, et al. Dostarlimab and niraparib in primary advanced ovarian cancer. Ann Oncol. 2025 Dec;36(12):1503-1513. 
11. Chan N, Bristow RG. "Contextual" synthetic lethality and/or loss of heterozygosity: tumor hypoxia and modification of DNA repair. Clin Cancer Res. 2010 Sep 15;16(18):4553-60.
12. Rahimi N. The ubiquitin-proteasome system meets angiogenesis. Mol Cancer Ther. 2012 Mar;11(3):538-48.
13. Colombo N, Sessa C, du Bois A, et al. ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease†. Ann Oncol. 2019 May 1;30(5):672-705. 
14. Moore KN, Angelergues A, Konecny GE, et al. Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer. N Engl J Med. 2023 Dec 7;389(23):2162-2174.
15. Olawaiye AB, Gladieff L, O'Malley DM, et al. Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): an open-label, randomised, controlled, phase 3 trial. Lancet. 2025 Jun 21;405(10496):2205-2216. 
16. Colombo N, et al. Pembrolizumab vs placebo plus weekly paclitaxel ± bevacizumab in platinum-resistant recurrent ovarian cancer: results from the randomized double-blind phase 3 ENGOT-ov65/KEYNOTE-B96 study. ESMO Congress Berlín. 2025.
17. Colombo N, et al. Pembrolizumab vs placebo plus weekly paclitaxel ± bevacizumab in platinum-resistant recurrent ovarian cancer: results from the randomized double-blind phase 3 ENGOT-ov65/KEYNOTE-B96 study. ESGO Congress Copenhagen. 2026.

ES-40866 Marzo 2026